FerrariABrechtIBGattaG, et al. Defining and listing very rare cancers of pediatric age: consensus of the Joint Action on Rare Cancers (JARC) in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). Eur J Cancer2019; 110: 120–126.
2.
FerrariATramaADe PaoliA, et al. Access to clinical trials for adolescents with soft tissue sarcomas: enrolment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. Pediatr Blood Cancer2017; 64: 6.
3.
FerrariADamaEPessionA, et al. Adolescents with cancer in Italy: entry into the national cooperative pediatric oncology group AIEOP trials. Eur J Cancer2009; 45: 328–334.
4.
SkapekSFerrariAGuptaA, et al. Rhabdomyosarcoma. Nature Rev Dis Primers2019; 5: 1.
5.
BisognoGJenneyMBergeronC, et al; European paediatric Soft tissue sarcoma Study Group. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol2018; 19: 1061–1071.
6.
BisognoGDe SalvoGLBergeronC, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol Epub 2019 Sept 24.
7.
CasanovaMFerrariASpreaficoF, et al. Vinorelbine in previously treated advanced childhood sarcomas: evidence of activity in rhabdomyosarcoma. Cancer2002; 94: 3263–3268.
8.
HillSALonerganSJDenekampJ, et al. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer1993; 29A: 1320–1324.
9.
HillSASampsonLEChaplinDJ.Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer1995; 63: 119–123.
10.
MaJWaxmanDJ.Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther2008; 7: 79–89.
11.
HanahanDBergersGBergslandE.Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest2000; 105: 1045–1047.
12.
CasanovaMFerrariABisognoG, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer2004; 101: 1664–1671.
13.
KlingebielTBoosJBeskeF, et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high-dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer2008; 50: 739–745.
14.
MaurerHMBeltangadyMGehanEA, et al. The Intergroup Rhabdomyosarcoma Study: I: a final report. Cancer1988; 61: 209–220.
15.
MaurerHMGehanEABeltangadyM, et al. The Inter-group Rhabdomyosarcoma Study: II. Cancer1993; 71: 1904–1922.
16.
CristWGehanEARagabAH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol1995; 13: 610–630.
17.
CristWMAndersonJRMezaJL, et al. Intergroup Rhabdomyosarcoma Study: IV: results for patients with nonmetastatic disease. J Clin Oncol2001; 19: 3091–3102.
18.
SpuntSLSmithLMRuymannFB, et al. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Clin Cancer Res2004; 10: 6072–6079.
19.
ArndtCAStonerJAHawkinsDS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children’s Oncology Group Study D9803. J Clin Oncol2009; 27: 5182–5188.
20.
ArndtCASBisognoGKoscielniakE. Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. Cancer Treat Rev2018; 68: 94–101.
21.
HawkinsDSChiYYAndersonJR, et al. Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol2018; 36: 2770–2777.
22.
FlamantFRodaryCReyA, et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence: results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer1998; 34: 1050–1062.
23.
OberlinOReyASanchez de ToledoJ, et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol2012; 30: 2457–2465.
24.
StevensMCReyABouvetN, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology: SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol2005; 23: 2618–2628.
25.
MeyerWH. Maintenance chemotherapy in rhabdomyosarcoma: the new standard of care. Lancet Oncol Epub 2019 Sept 24.
26.
OlsonTASchneiderDTBrechtIB, et al. Rare tumors: a different perspective on oncology. In: SchneiderDTBrechtIBOlsonTAFerrariA, eds. Rare Tumors in Children and Adolescents. Berlin: Springer; 2012: 3–15.
27.
FerrariATramaADePA, et al. Access to clinical trials for adolescents with soft tissue sarcomas: enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. Pediatr Blood Cancer2017; 64: 6.
28.
OberlinOReyABrownKL, et al. Prognostic factors for outcome in localized extremity rhabdomyosarcoma: pooled analysis from four international cooperative groups. Pediatr Blood Cancer2015; 62: 2125–2131.
29.
KutteschJFJrKrailoMDMaddenT, et al; Children’s Oncology Group. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children’s Oncology Group study. Pediatr Blood Cancer2009; 53: 590–593.
30.
PappoASLydenEBreitfeldP, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children’s Oncology Group. J Clin Oncol2007; 25: 362–369.
31.
MascarenhasLLydenERBreitfeldPP, et al. Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol2010; 28: 4658–4663.
32.
Minard-CollinVIchanteJLNguyenL, et al. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma: a report from the Société Française des Cancers et Leucémies de l’Enfant et de l’Adolescent (SFCE). Eur J Cancer2012; 48: 2409–2416.
33.
GaspariniPFortunatoODe CeccoL, et al. Age-related alterations in immune contexture are associated with aggressiveness in rhabdomyosarcoma. Cancers2019; 11: E1380.
34.
JoshiDAndersonJRPaidasC, et al. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr Blood Cancer2004; 42: 64–73.
35.
TramaABottaLFoschiR, et al. Survival of European adolescents and young adults diagnosed with cancer in 2000-2007: latest EUROCARE-5 results. Oncology2016; S1470-2045(16)00162-5.
36.
SultanIQaddoumiIYaserS, et al. Comparing adult and pediatric rhabdomyosarcoma in the Surveillance, Epidemiology and End Results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol2009; 27: 3391–3397.
37.
FerrariADileoPCasanovaM, et al. Rhabdomyosarcoma in adults: a retrospective analysis of 171 patients treated at a single institution. Cancer2003; 98: 571–580.
38.
BergamaschiLBertulliRCasanovaM, et al. Rhabdomyo-sarcoma in adults: analysis of treatment modalities in a prospective single-center series. Med Oncol2019; 36: 59.
39.
van der GraafWTAOrbachDJudsonIR, et al. Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts. Lancet Oncol2017; 18: e166–e175.
40.
FerrariABleyerAPatelS, et al. The challenge of the management of adolescents and young adults with soft tissue sarcomas. Pediatr Blood Cancer2018; 65: e27013.
41.
FerrariAGaspariniPGillJ, et al. Challenges of clinical management of adolescents and young adults with bone and soft tissue sarcoma. Cancer J 2018; 24: 301–306.
